Larimar Therapeutics Statistics
Total Valuation
LRMR has a market cap or net worth of $576.61 million. The enterprise value is $405.53 million.
Important Dates
The next estimated earnings date is Monday, March 23, 2026, before market open.
| Earnings Date | Mar 23, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LRMR has 108.59 million shares outstanding. The number of shares has increased by 20.08% in one year.
| Current Share Class | 108.59M |
| Shares Outstanding | 108.59M |
| Shares Change (YoY) | +20.08% |
| Shares Change (QoQ) | +22.33% |
| Owned by Insiders (%) | 0.93% |
| Owned by Institutions (%) | 32.53% |
| Float | 70.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.27 |
| P/TBV Ratio | 4.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.06, with a Debt / Equity ratio of 0.03.
| Current Ratio | 4.06 |
| Quick Ratio | 3.91 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -78.24% and return on invested capital (ROIC) is -50.33%.
| Return on Equity (ROE) | -78.24% |
| Return on Assets (ROA) | -42.99% |
| Return on Invested Capital (ROIC) | -50.33% |
| Return on Capital Employed (ROCE) | -98.27% |
| Weighted Average Cost of Capital (WACC) | 9.68% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.03M |
| Employee Count | 65 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +81.23% in the last 52 weeks. The beta is 1.00, so LRMR's price volatility has been similar to the market average.
| Beta (5Y) | 1.00 |
| 52-Week Price Change | +81.23% |
| 50-Day Moving Average | 3.57 |
| 200-Day Moving Average | 3.53 |
| Relative Strength Index (RSI) | 68.91 |
| Average Volume (20 Days) | 9,039,888 |
Short Selling Information
The latest short interest is 8.98 million, so 8.27% of the outstanding shares have been sold short.
| Short Interest | 8.98M |
| Short Previous Month | 8.77M |
| Short % of Shares Out | 8.27% |
| Short % of Float | 12.80% |
| Short Ratio (days to cover) | 7.96 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -139.77M |
| Pretax Income | -132.00M |
| Net Income | -132.00M |
| EBITDA | -139.43M |
| EBIT | -139.77M |
| Earnings Per Share (EPS) | -$1.95 |
Full Income Statement Balance Sheet
The company has $175.44 million in cash and $4.35 million in debt, with a net cash position of $171.09 million or $1.58 per share.
| Cash & Cash Equivalents | 175.44M |
| Total Debt | 4.35M |
| Net Cash | 171.09M |
| Net Cash Per Share | $1.58 |
| Equity (Book Value) | 139.04M |
| Book Value Per Share | 1.62 |
| Working Capital | 138.11M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$96.49 million and capital expenditures -$270,000, giving a free cash flow of -$96.76 million.
| Operating Cash Flow | -96.49M |
| Capital Expenditures | -270,000 |
| Free Cash Flow | -96.76M |
| FCF Per Share | -$0.89 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LRMR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.08% |
| Shareholder Yield | -20.08% |
| Earnings Yield | -22.89% |
| FCF Yield | -16.78% |
Analyst Forecast
The average price target for LRMR is $16.14, which is 203.96% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.14 |
| Price Target Difference | 203.96% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -0.66% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |